| Literature DB >> 35627996 |
Anke-Verena Benecke1,2, Kira Leandra Schmidt1,2, Hannah Dinse1,2, Adam Schweda1,2, Lisa Jahre1,2, Madeleine Fink1,2, Benjamin Weismüller1,2, Nora Dörrie1,2, Matthias Welsner3, Eva-Maria Skoda1,2, Alexander Bäuerle1,2, Venja Musche1,2, Martin Teufel1,2.
Abstract
People with cystic fibrosis (pwCF) face great challenges during the ongoing COVID-19 pandemic. Recent research found equal levels of distress in pwCF and healthy controls (HC). The current study aimed to investigate the mental health burden and safety behavior in pwCF. Sixty-nine adult pwCF and sixty-nine propensity-score-matched HC participated in this study. Participants completed an anonymous online questionnaire assessing distress, generalized anxiety, depressive symptoms, COVID-19-related variables, self-reported adherent safety behavior (ASB), and dysfunctional safety behavior (DSB). PwCF showed equal amounts of distress (W = 2481.0, p = 0.669), depressive symptoms (W = 2632.5, p = 0.268), and generalized anxiety symptoms (W = 2515.5, p = 0.565) compared to the HC. COVID-19-related fear (W = 1872.0, p = 0.028), ASB (W = 1630.0, p = 0.001), and DSB (W = 1498.5, p < 0.001) were significantly elevated in pwCF. The pwCF estimated that the probability of suffering from symptoms (W = 954.5, p < 0.001), experiencing a severe course (W = 806.5, p < 0.001), or dying (W = 1079.0, p < 0.001) from COVID-19 is significantly higher than that of the HC. ASB was associated with a CF diagnosis, COVID-19-related fear, and a subjective level of information (R2 = 0.414, F(13, 124) = 6.936, p ≤ 0.001). DSB was associated with a diagnosis of CF and COVID-19-related fear (R2 = 0.196, F(13, 124) = 3.169, p ≤ 0.001). The data suggest that pwCF show functional and adequate behaviors towards the risk caused by the pandemic. Therefore, functional coping behaviors may provide advantages in addressing pandemic challenges.Entities:
Keywords: COVID-19; SARS-CoV-2; coping; cystic fibrosis; mental health burden; safety behavior
Year: 2022 PMID: 35627996 PMCID: PMC9142094 DOI: 10.3390/healthcare10050858
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Sociodemographic data.
| People with CF | Healthy Controls | ||||
|---|---|---|---|---|---|
|
| % |
| % |
| |
|
| 1 | ||||
| Female | 59 | 85.5 | 60 | 87.0 | |
| Male | 10 | 14.5 | 9 | 13.0 | |
|
| 0.984 | ||||
| 18–24 years | 11 | 15.9 | 9 | 13.0 | |
| 25–34 years | 22 | 31.9 | 25 | 36.2 | |
| 35–44 years | 20 | 29.0 | 21 | 30.4 | |
| 45–54 years | 11 | 15.9 | 9 | 13.0 | |
| 55–64 years | 4 | 5.8 | 4 | 5.8 | |
| 65–74 years | 1 | 1.4 | 1 | 1.4 | |
|
| 0.935 | ||||
| Single | 20 | 29.0 | 20 | 29.0 | |
| Married | 25 | 36.2 | 26 | 37.7 | |
| In a relationship | 17 | 24.6 | 17 | 24.6 | |
| Divorced/separated | 4 | 5.8 | 2 | 2.9 | |
| Others | 3 | 4.3 | 4 | 5.8 | |
|
| 0.959 | ||||
| University education | 21 | 30.4 | 22 | 31.9 | |
| Higher education entrance qualification | 22 | 31.9 | 24 | 34.8 | |
| Intermediate secondary education | 18 | 26.1 | 17 | 24.6 | |
| Lower secondary education | 3 | 4.3 | 3 | 4.3 | |
| Others | 5 | 7.2 | 3 | 4.3 | |
|
| 0.995 | ||||
| 100,000 residents | 18 | 26.1 | 18 | 26.1 | |
| 20,000 residents | 20 | 29.0 | 20 | 29.0 | |
| 5000 residents | 10 | 14.5 | 11 | 15.9 | |
| <5000 residents | 21 | 30.4 | 20 | 29.0 | |
|
| 1 | ||||
| yes | 14 | 20.3 | 13 | 18.8 | |
| no | 55 | 79.7 | 56 | 81.2 | |
|
| 69 | 100 | 69 | 100 | |
Comparisons between people with CF and healthy controls.
| People with CF ( | Healthy Controls ( | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| Distress | 5.38 (2.79) | 6 (5) | 5.55 (2.89) | 6 (5) | 2481.0 | 0.669 | 0.042 |
| Generalized anxiety symptoms | 6.0 (4.00) | 5 (5) | 7.26 (5.86) | 5 (6) | 2515.5 | 0.565 | 0.057 |
| Depressive symptoms | 1.52 (1.39) | 2 (2) | 2.03 (1.95) | 2 (3) | 2632.5 | 0.268 | 0.106 |
| COVID-19-related fear | 4.91 (1.82) | 5 (2) | 4.22 (1.90) | 5 (3) | 1872.0 | 0.028 * | −0.214 |
| Subjective level of information | 6.01 (0.76) | 6 (1.33) | 5.80 (1.0) | 6 (1) | 2091.5 | 0.213 | −0.121 |
| ASB | 6.28 (0.97) | 6.75 (1) | 5.48 (1.58) | 6 (2) | 1630.0 | 0.001 ** | −0.315 |
| DSB | 3.46 (1.48) | 3.67 (2.33) | 2.52 (1.5) | 2 (1.67) | 1498.5 | <0.001 ** | −0.371 |
|
| |||||||
| Infection with COVID-19 | 47.94 (24.88) | 50 (35) | 51.09 (27.57) | 50 (40) | 2546.0 | 0.48 | 0.07 |
| Suffering from symptoms | 74.59 (25.45) | 80 (49) | 46.93 (22.55) | 50 (30) | 954.5 | <0.001 ** | −0.599 |
| Having a severe course | 58.9 (27.77) | 50 (30) | 24.06 (20.42) | 20 (32) | 806.5 | <0.001 ** | −0.661 |
| Dying of COVID-19 | 36.33 (31.07) | 35 (49) | 9.84 (14.24) | 3 (8) | 1079.0 | <0.001 ** | −0.547 |
| Risk that others contract COVID-19 | 63.43 (28.56) | 70 (36) | 63.68 (31.22) | 70 (40) | 2440.5 | 0.799 | 0.025 |
Note. Mean parameter values and median for each of the analyses are shown for people with CF (n = 69) and healthy controls (n = 69), as well as the results of Wilcoxon-signed-rank tests (assuming unequal variance). ASB = adherent safety behavior, DSB = dysfunctional safety behavior. ** p ≤ 0.01 * p ≤ 0.05.
Figure 1Distribution of risk perception, in percent (%), in people with cystic fibrosis (pwCF) compared to healthy controls (HC), regarding (a) risk of infection with COVID-19, (b) presenting symptoms of COVID-19, (c) having a severe course of COVID-19, (d) risk of dying of COVID-19, and (e) risk that others contract COVID-19. For descriptive statistics see Table 2.